Form 4: Tenax Therapeutics Interim CFO Granted 50,000 Stock Options

Tenax Therapeutics' Interim CFO, Thomas McGauley, was granted 50,000 stock options with a future vesting schedule.

Summary

• Thomas McGauley, the Interim CFO of Tenax Therapeutics, Inc. (TENX), was granted 50,000 stock options.
• The stock options have an exercise price of $12.51 per share and are set to expire on January 30, 2029.
• The vesting schedule for these options is split into two tranches: 50% will vest on January 30, 2026, and the remaining 50% will vest on May 31, 2026, both contingent upon Mr. McGauley's continuous service to the Issuer.
• Following this reported transaction, Mr. McGauley directly beneficially owns 50,000 derivative securities (stock options) and 2,000 shares of common stock.
• Additionally, Mr. McGauley indirectly beneficially owns 1,000 shares of common stock through a child and 5,000 shares through a spouse.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, as it represents a standard executive compensation practice that aligns the Interim CFO's interests with the company's long-term performance, though it doesn't reflect immediate operational or financial improvements.

Positives

• The grant of 50,000 stock options to the Interim CFO aligns management's incentives with long-term shareholder value creation.
• The structured vesting schedule encourages the executive's continued commitment and service to the company.

Negatives

• The options do not provide immediate cash flow to the executive, as they require future vesting and exercise.
• The exercise price of $12.51 means the company's stock price must appreciate above this level for the options to be profitable.

Future Outlook

The stock options granted to the Interim CFO are subject to a future vesting schedule, with 50% vesting on January 30, 2026, and the remaining 50% on May 31, 2026, contingent on continuous service to the Issuer.

Industry Context

Stock option grants are a standard component of executive compensation packages across various industries, particularly in biotechnology and pharmaceuticals, to incentivize performance and retention. StockSavvy.ai notes that such grants aim to align executive interests with long-term shareholder value creation.

Related Party Transactions

• Indirect beneficial ownership of 1,000 common shares through a child.
• Indirect beneficial ownership of 5,000 common shares through a spouse.

Stakeholder Impact

• Shareholders: Potential positive impact through improved executive alignment and retention, but also potential future dilution if options are exercised.
• Management: The Interim CFO receives a significant incentive package, enhancing personal stake in company performance.

Next Steps

• 50% of the granted stock options will vest on January 30, 2026.
• The remaining 50% of the granted stock options will vest on May 31, 2026.

Key Dates

Keywords

Tenax Therapeutics, TENX, Form 4, Insider Transaction, Stock Options, Executive Compensation, Thomas McGauley, CFO, Beneficial Ownership